Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MiNK Therapeutics, Inc. (NASDAQ: INKT) SEC filings page provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies, MiNK uses its SEC reports to describe material agreements, financing activities, governance decisions, and key clinical and corporate milestones.
Current reports on Form 8-K are particularly relevant for tracking MiNK’s business. Recent 8-K filings have covered topics such as the appointment of new board members, entry into an at-the-market equity sales agreement, the announcement of quarterly financial results, and updates on clinical and translational data for its iNKT programs. These filings often incorporate press releases that summarize clinical progress with agenT-797 in solid tumors, GvHD, and pulmonary immune failure, as well as grant awards and collaborations with academic institutions.
Investors can also use MiNK’s SEC filings to monitor capital-raising transactions, including at-the-market offerings registered on Form S-3 and described in accompanying 8-Ks, and to review governance and shareholder matters such as annual meeting results and director elections. Over time, annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide more detailed information on risk factors, research and development activities, and the financial condition of the company.
On Stock Titan, MiNK’s filings are updated in near real time from EDGAR, and AI-powered tools can help summarize lengthy documents, highlight key sections, and surface items such as material agreements or equity programs. Users can also review insider-related disclosures when Forms 3, 4, or 5 are filed, offering additional context on management and director equity activity in relation to the company’s clinical and strategic developments.
MiNK Therapeutics director Brian Corvese received a new stock option grant. On January 2, 2026, he was awarded options to buy 5,395 shares of MiNK Therapeutics common stock at an exercise price of $11.12 per share. These options vest on February 2, 2026, as long as he continues to serve on the company’s board through that date. The options expire on January 2, 2036, and were acquired at a price of $0.00, reflecting a compensatory equity award rather than a market purchase.
MiNK Therapeutics director reports new stock-based compensation. A company director received 1,263 restricted stock units (RSUs) of MiNK Therapeutics, Inc. common stock on 12/01/2025 at a value of $11.09 per share. These RSUs were granted in lieu of cash retainers for board and committee service and will vest one month after the grant date, at which point each RSU converts into one share of common stock. After this grant, the director beneficially owns 20,234 shares directly and 27,830 shares indirectly through an irrevocable trust established for the benefit of the director’s family.
MiNK Therapeutics (INKT) filed its Q3 2025 10‑Q, reporting continued losses and a going concern disclosure. Net loss was $2.89M for the quarter and $9.89M year‑to‑date. Cash and cash equivalents were $14.28M as of September 30, 2025.
The company raised liquidity via its at‑the‑market program, selling about 488,000 shares in Q3 for net proceeds of $13.14M, and an additional ~88,000 shares for $1.2M through November 13, 2025. A related party convertible note carried $5.0M principal and ~$154,000 accrued interest, with fair value of ~$5.7M at quarter‑end. Due to related parties totaled $15.04M.
Operating expenses reflected R&D of $1.14M and G&A of $1.85M for Q3. Net cash used in operations was $3.85M for the nine months. The company executed a 1‑for‑10 reverse stock split effective January 28, 2025, regained Nasdaq MVLS compliance on July 28, 2025, and is no longer a Nasdaq “Controlled Company.” Shares outstanding were 4,694,155 as of November 13, 2025. Management states substantial doubt exists about continuing as a going concern for one year after filing, while pursuing financing and partnerships.
MiNK Therapeutics filed a shelf registration to offer up to $150,000,000 of common stock, preferred stock, warrants, debt securities, and units. A related prospectus supplement establishes an at‑the‑market (ATM) program to sell up to $50,000,000 of common stock through B. Riley Securities, Inc.
Sales under the ATM are constrained by General Instruction I.B.6; based on a public float of $35,031,699 as of November 6, 2025, MiNK may currently sell up to $6,641,284 under the ATM. The Sales Agent’s compensation is 3.0% of gross proceeds. The company may sell directly, through agents, or via underwriters as described in the plan of distribution.
MiNK intends to use any net proceeds for working capital and general corporate purposes, including research and development, clinical programs, potential in‑licensing or acquisitions, collaborations, and capital expenditures.
MiNK Therapeutics insider Jennifer Buell amended a previously reported Form 4 to disclose that 5,351 shares of common stock were withheld to cover withholding taxes related to stock issued to her on 09/09/2025. The amended entry shows those withheld shares were disposed at a price of $15.36, leaving the reporting person with 36,492 shares beneficially owned. The amendment corrects an omission in the original Form 4 that did not include the tax-withheld shares in Table I.
MiNK Therapeutics reported a change in its board of directors. On September 23, 2025, the company’s Board elected Dr. John Holcomb as a Class II director, with his initial term ending at the 2026 annual meeting of stockholders. This adds new expertise to the board without changing its overall structure.
In connection with his election, Dr. Holcomb received a stock option to purchase 4,174 shares of MiNK common stock under the 2021 Equity Incentive Plan and the non-employee director compensation program. The option has a 10-year term, an exercise price set at the closing market price on the grant date, and vests in three equal annual installments as long as he continues to serve. As a non-employee director, he is also eligible for cash and potential additional equity compensation under the same program.
MiNK Therapeutics insider grant: Chief Executive Officer Jennifer Buell received 18,229 shares of common stock and a stock option to purchase 50,000 shares on September 9, 2025, as part of her 2024 performance bonus. The issued shares were valued at $15.36 per share on the grant date and are fully vested on issuance but subject to a lockup that releases 100% on October 9, 2025. The option has an exercise price of $15.36, vests over three years (one-third at the first anniversary, then eight equal quarterly installments) and expires September 9, 2035. Following the transactions, Buell beneficially owned 41,913 shares and held 50,000 options.
MiNK Therapeutics director Robert Peter Kadlec was granted a stock option to buy 3,225 shares of common stock at an exercise price of $15.36 per share on 09/09/2025. The option is an award that vests in full on the one-year anniversary of the grant date if Mr. Kadlec remains on the board and expires on 09/09/2035. The Form 4 was filed for the reporting person identified at a New York address and signed by an attorney-in-fact on 09/11/2025. No cash proceeds were reported at the time of filing.
MiNK Therapeutics director Peter Behner was granted a stock option on 09/09/2025 to buy 3,225 shares of common stock at an exercise price of $15.36 per share. The option was reported on Form 4 filed 09/11/2025 and is exercisable through 09/09/2035. The option vests in full on the one-year anniversary of the grant date provided Mr. Behner continues to serve on the company's board through that date. Following the grant, Mr. Behner beneficially owns 3,225 shares via this option, held directly.
MiNK Therapeutics insider grant to director Brian Corvese: The filing reports a stock option grant awarding the Reporting Person the right to buy 3,225 shares of MiNK Therapeutics common stock at an exercise price of $15.36 per share. The transaction date is listed as 09/09/2025 and the option shows an expiration date of 09/09/2035 in the table. The form states the option "vests in full on the one-year anniversary of the date of grant" provided the reporting person continues to serve on the company’s board through that date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.